Abstract
Background
In general, late side effects after salvage radiotherapy (RT) for prostate cancer are below 10%. Patients with impaired DNA repair ability and genetic instability can have significantly increased reactions after RT.
Case, clinical follow-up, and examination
We present a patient who experienced severe side effects after additive RT for prostate cancer and died from the complications 25 months after RT. Imaging (MR) is shown as well as three-color fluorescence in situ hybridization. The blood sample testing revealed that radiosensitivity was increased by 35–55%. We undertook a review of the literature to give an overview over the tests established that are currently considered useful.
Conclusion
This case highlights that the identification of patients with increased radiosensitivity is an important task in radiation protection. Groups of patients who should be screened have to be found and corresponding research facilities have to be set up.
Zusammenfassung
Hintergrund
Generell sind späte Nebenwirkungen nach additiver Radiotherapie (RT) beim Prostatakarzinom mit deutlich unter 10 % selten. Allerdings haben Patienten mit eingeschränkter DNA-Reparatur-Kapazität und genetischer Instabilität ein signifikant erhöhtes Nebenwirkungsrisiko.
Fallbericht, Follow-up und Untersuchungsergebnisse
In diesem Fallbeispiel stellen wir einen Patienten vor, der nach additiver RT wegen Prostatakarzinom massive Nebenwirkungen erlitt und 25 Monate nach der RT daran verstarb. Wir zeigen die Ergebnisse der konsekutiven MR-Untersuchungen und 3‑Farben-Fluoreszenz-in-situ-Hybridisierung. Die Blutuntersuchung ergab eine um 35–55 % erhöhte Strahlenempfindlichkeit. Eine aktuelle Literaturrecherche ergab, dass mittlerweile verschiedene Testverfahren zur Untersuchung der Strahlenempfindlichkeit etabliert sind.
Schlussfolgerung
Das Fallbeispiel zeigt, dass die Identifikation besonders strahlenempfindlicher Patienten ein wichtiges Arbeitsziel im Strahlenschutz ist. Patientenparameter für eine erforderliche Testung über die bekannten Syndrome hinaus sollten identifizierbar werden. Entsprechende Forschungseinrichtungen sind zu etablieren.
References
Chen S‑L, Wang S‑C, Ho C‑J et al (2017) Prostate cancer mortality-to-incidence ratios are associated with cancer care disparities in 35 countries. Sci Rep. https://doi.org/10.1038/srep40003
http://www.awmf.org/uploads/tx_szleitlinien/043-022OLl_S3_Prostatakarzinom_2016-12.pdf. Accessed 30 March 2017
Thompson IM, Tangen C, Paradelo J et al (2009) Adjuvant Radiotherapy for Pathologic T3N0M0 Prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956–962
Moinpour CM, Darke AK, Donaldson GW, Cespedes D, Johnson CR, Ganz PA, Patrick DL, Ware JE Jr, Shumaker SA, Meyskens FL, Thompson IM Jr. (2012) Health-related quality-of-life findings for the prostate cancer prevention trial. J Natl Cancer Inst 104(18):1373–1385
Strasser H, Grabenbauer GG, Sprung CN et al (2007) DNA double-strand break induction and repair in irradiated lymphoblastoid, fibroblast cell lines and white blood cells from ATM, NBS and radiosensitive patients. Strahlenther Onkol 183:447. https://doi.org/10.1007/s00066-007-1683-4
Djuzenova CS, Elsner I, Katzer A et al (2013) Radiosensitivity in breast cancer assessed by the histone γ‑H2AX and 53BP1 foci. Radiat Oncol 8:98
Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A (2017) Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay. Oncol Rep 37(3):1379–1138
Hart RM, Kimler BF, Evans RG et al (1987) Radiotherapeutic management of medulloblastoma in a pediatric patient with ataxia teleangiectasia. Int J Radiat Oncol Biol Phys 13:1237–1240
Lederman RJ, Wilbourn AJ (1984) Brachial plexopathy: recurrent cancer or radiation? Neurology 34:1331–1335
Neubauer S, Dunst J, Gebhart E (1997) The impact of complex chromosomal rearrangements on the detection of radiosensitivity in cancer patients. Radiother Oncol 43(2):189–195
Keller U, Kuechler A, Liehr T, Muller E, Grabenbauer G, Sauer R, Distel L (2004) Impact of various parameters in detecting chromosomal aberrations by FISH to describe radiosensitivity. Strahlenther Onkol 180(5):289–296
Carney JP (1999) Chromosomal breakage syndromes. Curr Opin Immunol 11:443–447
Distel L, Neubauer S, Varon R et al (2003) Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med Pediatr Oncol 41:44–48
Willers H, Gheorghiu L, Liu Q (2015) DNA damage response assessments in human tumor samples provide functional biomarkers of radiosensitivity. Semin Radiat Oncol 25(4):237. https://doi.org/10.1016/j.semradonc.2015.05.007
Neubauer S, Liehr T, Birkenhake S et al (1998) Estimation of DNA single-strand breaks by single cells gel electrophoresis in tumor cells. Genet Anal 14:121–124
Sak A, Grehl S, Erichsen P et al (2007) gamma-H2AX foci formation in peripheral blood lymphocytes of tumor patients after local radiotherapy to different sites of the body: dependence on the dose-distribution, irradiated site and time from start of treatment. Int J Radiat Biol 83:639–652
Van Oorschot B, Hovingh SE, Moerland PD (2014) Reduced activity of double-strand break repair genes in prostate cancer patients with late normal tissue radiation toxicity. Int J Radiat Oncol Biol Phys 88:664–670
Auer J, Keller U, Schmidt M et al (2014) Individual radiosensitivity in a breast cancer collective is changed with the patients’ age. Radiol Oncol 48:80–86
Distel L, Neubauer S, Keller U et al (2006) Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. Radiother Oncol 81:257–263
Kerns SL, Ostrer H, Rosenstein B (2014) Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy. Cancer Discov 4:155–165
Leong T, Chao M, Bassal S et al (2003) Radiation-hypersensitive cancer patients do not manifest protein expression abnormalities in components of the nonhomologous end-joining (NHEJ) pathway. Br J Cancer 88:1251–1255
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fahrig, A., Koch, T., Lenhart, M. et al. Lethal outcome after pelvic salvage radiotherapy in a patient with prostate cancer due to increased radiosensitivity. Strahlenther Onkol 194, 60–66 (2018). https://doi.org/10.1007/s00066-017-1207-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-017-1207-9